EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease

Adrian Boicean, Dan Bratu iD, Sorin Radu Fleaca iD, Gligor Vasile, Leeb Shelly, Sabrina Birsan iD, Ciprian Bacila iD, Adrian Hasegan

Pathogens · 09.09.2023 · 12 (9) · 1149

DOI: 10.3390/pathogens12091149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 09.09.2023. Verfasst von Adrian Boicean und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerul Cercetării și Inovării, Ministry of Research, Innovation, and Digitization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review explores the potential benefits of fecal microbiota transplantation (FMT) as an adjunct treatment in tuberculosis (TB), drawing parallels from its efficacy in inflammatory bowel disease (IBD). FMT has shown promise in restoring the gut microbial balance and modulating immune responses in IBD patients. Considering the similarities in immunomodulation and dysbiosis between IBD and TB, this review hypothesizes that FMT may offer therapeutic benefits as an adjunct therapy in TB.

Methods

We conducted a systematic review of the existing literature on FMT in IBD and TB, highlighting the mechanisms and potential implications of FMT in the therapeutic management of both conditions. The findings contribute to understanding FMT’s potential role in TB treatment and underscore the necessity for future research in this direction to fully leverage its clinical applications.

Conclusion

The integration of FMT into the comprehensive management of TB could potentially enhance treatment outcomes, reduce drug resistance, and mitigate the side effects of conventional therapies. Future research endeavors should focus on well-designed clinical trials to develop guidelines concerning the safety and short- and long-term benefits of FMT in TB patients, as well as to assess potential risks.

Schlagwörter

Stichwörter der Autor:innen

FMTIBDTBadjunct therapydysbiosisfecal microbiota transplantationgut microbiotaimmunomodulationinflammatory bowel diseasetuberculosis

Autor:innen und Institutionen

  • Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania.
  • County Clinical Emergency Hospital of Sibiu, 550245 Sibiu, Romania.

ORCID-Profile: Dan Bratu, Sorin Radu Fleaca, Sabrina Birsan, Ciprian Bacila

Förderung

  • Ministerul Cercetării și Inovării
  • Ministry of Research, Innovation, and Digitization

Zitieren

APA

Boicean, A., Bratu, D., Fleaca, S. R., Vasile, G., Shelly, L., Birsan, S., Bacila, C., & Hasegan, A. (2023). Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease. Pathogens, 12(9), 1149. https://doi.org/10.3390/pathogens12091149

Vancouver

Boicean A, Bratu D, Fleaca SR, Vasile G, Shelly L, Birsan S, et al. Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease. Pathogens. 2023;12(9):1149. doi:10.3390/pathogens12091149

BibTeX
@article{Boicean2023,
  author = {Boicean, Adrian and Bratu, Dan and Fleaca, Sorin Radu and Vasile, Gligor and Shelly, Leeb and Birsan, Sabrina and Bacila, Ciprian and Hasegan, Adrian},
  title = {Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease},
  journal = {Pathogens},
  year = {2023},
  volume = {12},
  number = {9},
  pages = {1149},
  doi = {10.3390/pathogens12091149}
}
Kostenlos starten →